Enalapril-HL (enalapril) tablets №20


Manufacturer: Poland

Treatment of arterial hypertension; treatment of clinically expressed heart failure; prevention of clinically expressed heart failure in patients with asymptomatic left ventricular dysfunction (ejection fraction ≤ 35 %).



Enalapril-HL Storage
active substances: enalapril, hydrochlorothiazide;

1 tablet contains enalapril maleate 10 mg, hydrochlorothiazide 12.5 mg;

Enalapril-HL Excipients: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, pregelatinized starch, potato starch, magnesium stearate, colloidal anhydrous silica, povidone.

Enalapril-HL Dosage form

Basic physical and chemical properties: tablets of white or white with a creamy shade of color, flat-cylindrical form with a line and a facet.

Pharmacotherapeutic group
Drugs acting on the renin-angiotensin system. Combined drugs of ACE inhibitors. Enalapril and diuretics. ATX code C09B A02.

Pharmacological properties
The drug contains a combination of two antihypertensive drugs. The antihypertensive effects of the two components complement each other and persist for 24 hours. The presence of enalapril reduces the potassium loss associated with hydrochlorothiazide.

Pharmacodynamics. Enalapril is a highly specific competitive ACE antagonist, a prodrug that is converted to the active metabolite enalaprilat in the body.

Enalaprilat inhibits ACE activity, as a result of which angiotensin I is not converted to angiotensin II, a substance that has a significant vasoconstrictive effect, also reduces aldosterone secretion, thereby reducing the concentration of angiotensin II and aldosterone in the blood. Inhibits the breakdown of bradykinin, which is a powerful vasopressor peptide. The mechanism by which enalapril lowers blood pressure is primarily associated with inhibition of the activity of the renin-angiotensin-aldosterone system (RAAS), which regulates blood pressure; Enalapril may have an antihypertensive effect even in patients with low-renin hypertension.

The pressor (sympathoadrenal) and depressor (kallikrein-kinin and prostaglandin) systems of the body are suppressed, the formation of vascular endothelial factor increases. As a result of these effects the general peripheral vascular resistance, arterial pressure, pressure in a small circle of blood circulation decreases, cardiac output increases. Enalapril causes a gradual decrease in systolic and diastolic blood pressure.

Hypertension in patients treated with combination therapy.

Hypersensitivity to enalapril and other angiotensin-converting enzyme (ACE) inhibitors, hydrochlorothiazide and other sulfonamide derivatives or to other components of the drug; history of angioneurotic edema associated with prior treatment with ACE inhibitors; hereditary or idiopathic angioneurotic edema; patients with severe renal impairment (creatinine clearance less than 30 ml / min or serum creatinine level exceeds 265 μmol / l (3 mg / 100 ml), renal artery stenosis, contraindicated during hemodialysis, clinical condition after kidney transplantation, severe hepatic impairment, anuria, primary hyperaldosteronism, treatment-resistant hypokalaemia or hyperkalaemia, refractory hyponatraemia, symptomatic hyperuricaemia (gout), pregnant women or women planning to become pregnant (see “Use during pregnancy or breast-feeding”). with aliskiren-containing drugs in patients with diabetes mellitus or renal impairment (GFR <60 ml / min / 1.73 m2).